Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers (2024) Mottini C, Auciello FR, Manni I, Pilarsky C, Caputo D, Caracciolo G, Rossetta A, et al. Journal article, Review article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects (2024) Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon Mv, Subklewe M, et al. Journal article Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study (2024) Wies C, Schneider L, Haggenmüller S, Bucher TC, Hobelsberger S, Heppt M, Ferrara G, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study (2023) Medas F, Dobrinja C, Al-Suhaimi EA, Altmeier J, Anajar S, Arikan AE, Azaryan I, et al. Journal article Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors (2023) Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer (2023) Mlecnik B, Lugli A, Bindea G, Marliot F, Bifulco C, Lee JKJ, Zlobec I, et al. Journal article Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article